SKP1 and CCNA2

Number of citations of the paper that reports this interaction (PubMedID 9858587)
26

Data Source:
HPRD (in vivo)

		SKP1	CCNA2
Description		S-phase kinase associated protein 1	cyclin A2
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Centrosome Cytosol SCF Ubiquitin Ligase Complex Cul7-RING Ubiquitin Ligase Complex	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex
	Molecular Function	Protein Binding Beta-catenin Binding Protein Domain Specific Binding Cullin Family Protein Binding F-box Domain Binding Ubiquitin Ligase-substrate Adaptor Activity	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding
	Biological Process	Protein Polyubiquitination Protein Ubiquitination SCF-dependent Proteasomal Ubiquitin-dependent Protein Catabolic Process Histone H2A Monoubiquitination Maintenance Of Protein Location In Nucleus Protein K48-linked Ubiquitination Positive Regulation Of Ubiquitin Protein Ligase Activity	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Histone Phosphorylation Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus
Pathways		Activation of NF-kappaB in B cells Prolactin receptor signaling SCF-beta-TrCP mediated degradation of Emi1 Vpu mediated degradation of CD4 SCF(Skp2)-mediated degradation of p27/p21 Degradation of beta-catenin by the destruction complex Downstream TCR signaling NOTCH1 Intracellular Domain Regulates Transcription Regulation of PLK1 Activity at G2/M Transition Constitutive Signaling by NOTCH1 PEST Domain Mutants Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling FCERI mediated NF-kB activation Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Circadian Clock Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Orc1 removal from chromatin Cyclin D associated events in G1 FBXL7 down-regulates AURKA during mitotic entry and in early mitosis Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Neddylation Interleukin-1 signaling Iron uptake and transport Negative regulation of NOTCH4 signaling Regulation of BACH1 activity Nuclear events stimulated by ALK signaling in cancer Antigen processing: Ubiquitination & Proteasome degradation	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry
Drugs		1-naphthaleneacetic acid (2S)-2-(1H-indol-3-yl)hexanoic acid (2S)-2-(1H-indol-3-yl)pentanoic acid (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid Indoleacetic acid	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Mean platelet volume ( 32888494) Systemic lupus erythematosus ( 27399966 26502338)	Mean corpuscular hemoglobin ( 32888494)
Interacting Genes		82 interacting genes: ANKRD36BP1 APIP BTRC CACYBP CAND1 CCNA2 CDCA3 CDK2 CDK4 CDK9 CDKN1A CDKN1B CENPE CFLAR CTLA4 CUL1 CUL7 DDX19B FBH1 FBXL14 FBXL2 FBXL20 FBXL22 FBXL3 FBXL4 FBXL5 FBXL8 FBXO11 FBXO15 FBXO16 FBXO17 FBXO2 FBXO25 FBXO27 FBXO28 FBXO3 FBXO32 FBXO34 FBXO4 FBXO43 FBXO44 FBXO46 FBXO48 FBXO5 FBXO6 FBXO7 FBXO8 FBXO9 FBXW2 FBXW5 FBXW7 FBXW8 GHR GLMN GPS1 HSP90AA1 KCTD9 LAMTOR5 LMO2 MED21 MEOX2 MTUS1 MYC NFKBIA NFKBIB NFKBIE NUDT9P1 PPARGC1A PPP1CA PTEN RBX1 SEC23B SKP2 SUGT1 TBL1X TERF1 TRRAP TTC21A TTC9C TUBA4A UBE2D1 UHRF2	49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DRD2 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBTF USP37
Entrez ID		6500	890
HPRD ID		03255	00453
Ensembl ID		ENSG00000113558	ENSG00000145386
Uniprot IDs		P63208	P20248
PDB IDs		1FQV 1FS1 1FS2 1LDK 1P22 2ASS 2AST 2E31 2E32 2OVP 2OVQ 2OVR 3L2O 3WSO 4I6J 5IBK 5JH5 5K35 5V4B 5VZT 5VZU 5XYL 6BVA 6BYH 6C16 6M90 6M91 6M92 6M93 6M94 6O60 6TTU 6VCD 6W66 6WCQ 6WNX 7B5L 7B5M 7B5R	1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ 6SG4 7B5L 7B5R
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?